Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study

23 Jul 2021

Abstract excerpt

Naltrexone can aid in reducing alcohol consumption, while acamprosate supports abstinence; however, not all patients with alcohol use disorder (AUD) benefit from these treatments. Here we present the first genome-wide association study of AUD treatment outcomes based on data from the COMBINE and PREDICT studies of acamprosate and naltrexone, and the Mayo Clinic CITA study of acamprosate. Primary analyses focused...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Consumption and Health Effects
Share to Genetic Associations and Epidemiology
Share to Substance Abuse Treatment and Outcomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34302059
DOI: 10.1038/s41386-021-01097-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics studyPMID 34302059Read ↗

Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: A Genome-wide Pharmacogenomics StudySemantic proximity Read ↗

Human genetics and epigenetics of alcohol use disorder.Semantic proximity Read ↗

Advances in Medications and Tailoring Treatment for Alcohol Use DisorderSemantic proximity Read ↗

Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.Semantic proximity Read ↗

Bridging Genomics and Pharmacoepidemiology to Expand Treatment Options for Alcohol Use DisorderSemantic proximity Read ↗

Diverse types of genomic evidence converge on alcohol use disorder risk genes.Semantic proximity Read ↗

Genetic analysis of alcohol use disorder: GWAS of alcohol use disorders identification test (AUDIT) and polygenic risk scores in an east slavic population.Semantic proximity Read ↗

Pharmacogenetically driven treatments for alcoholism: are we there yet?Semantic proximity Read ↗

COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.Semantic proximity Read ↗

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation.Semantic proximity Read ↗

Epigenome-wide association study of alcohol consumption in N = 8161 individuals and relevance to alcohol use disorder pathophysiology: identification of the cystine/glutamate transporter SLC7A11 as a top targetSemantic proximity Read ↗

Gene expression differences associated with alcohol use disorder in human brainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.